Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

C B Westphalen¹, M G Krebs², C Le Tourneau^{3

4

5}, E S Sokol⁶, S L Maund⁷, T R Wilson⁷, D X Jin⁶, J Y Newberg⁶, D Fabrizio⁶, L Veronese⁸, M Thomas⁸, F de Braud^{9

10}

Affiliations

¹ Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. cwestpha@med.lmu.de.
² Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France, Saint-Cloud, France.
⁴ INSERM U900 Research Unit, Saint-Cloud, France.
⁵ Paris-Saclay University, Paris, France.
⁶ Foundation Medicine Inc., Cambridge, MA, USA.
⁷ Genentech Inc., South San Francisco, CA, USA.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ Department of Medical Oncology and Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁰ School of Specialisation in Medical Oncology, University of Milan, Milan, Italy.

Published Erratum

C B Westphalen et al. NPJ Precis Oncol. 2021.

. 2021 Sep 17;5(1):86.

doi: 10.1038/s41698-021-00222-y.

C B Westphalen¹, M G Krebs², C Le Tourneau^{3

4

5}, E S Sokol⁶, S L Maund⁷, T R Wilson⁷, D X Jin⁶, J Y Newberg⁶, D Fabrizio⁶, L Veronese⁸, M Thomas⁸, F de Braud^{9

10}

¹ Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. cwestpha@med.lmu.de.
² Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France, Saint-Cloud, France.
⁴ INSERM U900 Research Unit, Saint-Cloud, France.
⁵ Paris-Saclay University, Paris, France.
⁶ Foundation Medicine Inc., Cambridge, MA, USA.
⁷ Genentech Inc., South San Francisco, CA, USA.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ Department of Medical Oncology and Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁰ School of Specialisation in Medical Oncology, University of Milan, Milan, Italy.

No abstract available

Erratum for

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, Thomas M, de Braud F. Westphalen CB, et al. NPJ Precis Oncol. 2021 Jul 20;5(1):69. doi: 10.1038/s41698-021-00206-y. NPJ Precis Oncol. 2021. PMID: 34285332 Free PMC article.